Loading market dashboard
Avicanna Inc.
AVCNFHealthcareOTCCA
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Record revenue and gross profits driven by Canadian commercial growth and proprietary product expansion Continued advancement of pharmaceutical pipeline, medical affairs initiatives and international platform
Avicanna Inc. (AVCN:CA) Shareholder/Analyst Call Prepared Remarks Transcript
TORONTO, May 08, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce that all of management's nominees listed in the Company's management information circular dated April 2, 2026 (“Circular”) were elected as directors of the Company at its Annual General and Special Meeting of Shareholders held May 7, 2026 (“Meeting”).
TORONTO, May 01, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is announces that Eileen McCormack, who was not on the slate of directors for re-election or election as outlined in the circular at the upcoming annual general and special meeting of shareholders scheduled for Thursday May 7, 2026, has tendered her resignation as a member of the board of directors effective Friday May 1, 2026 ahead of the annual general and special meeting of shareholders.
TORONTO, May 01, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is announces that Eileen McCormack, who was not on the slate of directors for re-election or election as outlined in the circular at the upcoming annual general and special meeting of shareholders scheduled for Thursday May 7, 2026, has tendered her resignation as a member of the board of directors effective Friday May 1, 2026 ahead of the annual general and special meeting of shareholders.
Rescheduling aligns with Avicanna's established pharmaceutical and medical cannabis strategyRescheduling further supports advancement of R&D, clinical development, and medical affairs initiatives
TORONTO, April 21, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce that as previously disclosed its annual general and special meeting of shareholders will be held virtually on Thursday, May 7, 2026 at 11:30 AM (Toronto Time).
TORONTO, April 07, 2026 (GLOBE NEWSWIRE) -- ThreeD Capital Inc. (“ThreeD”) (CSE:IDK / OTCQX:IDKFF) a Canadian based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors, announces that through a series of transactions ending in recent weeks (the “Dispositions”), ThreeD disposed of ownership and control of an aggregate of 977,000 common shares (the “Subject Shares”) of Avicanna Inc. (the “Company” or “AVCN”). The Subject Shares represented approximately 0.8% of all issued and outstanding common shares of AVCN. As a result of the Dispositions, the percentage ownership held by ThreeD and Sheldon Inwentash (the “Joint Actor”) decreased by greater than 2%, on a partially diluted basis, from the last early warning report filed.
Avicanna Inc. (AVCN:CA) Q4 2025 Earnings Call Transcript
TORONTO, April 06, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products announces effective Thursday April 1, 2026 the resignation of John McVicar and pleased to announce the appointment of Mr. Ozgur Kilic to the Board of Directors of the Company.
Achieved positive adjusted EBITDA in Q4 2025 and near break-even $(0.29) million for the full year Advancements across business units, R&D, and clinical development to support scale and international growth
This marks the first commercial export of organic certified flower for SMGH The export represents the 21 st market for SMGH and 24 th market for all Avicanna products
New randomized controlled trial to evaluate dose-dependent effects of oral THC on anxiety and stress using Avicanna's proprietary capsules New randomized controlled trial to evaluate dose-dependent effects of oral THC on anxiety and stress using Avicanna's proprietary capsules
